IL259479B - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents
Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitorInfo
- Publication number
- IL259479B IL259479B IL259479A IL25947918A IL259479B IL 259479 B IL259479 B IL 259479B IL 259479 A IL259479 A IL 259479A IL 25947918 A IL25947918 A IL 25947918A IL 259479 B IL259479 B IL 259479B
- Authority
- IL
- Israel
- Prior art keywords
- fucose
- deoxy
- fluoro
- combination
- cancer treatment
- Prior art date
Links
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263228P | 2015-12-04 | 2015-12-04 | |
| US201662308583P | 2016-03-15 | 2016-03-15 | |
| US201662321857P | 2016-04-13 | 2016-04-13 | |
| PCT/US2016/064783 WO2017096274A1 (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL259479A IL259479A (en) | 2018-07-31 |
| IL259479B true IL259479B (en) | 2022-03-01 |
Family
ID=58797961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259479A IL259479B (en) | 2015-12-04 | 2018-05-21 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180353524A1 (OSRAM) |
| EP (1) | EP3383404A4 (OSRAM) |
| JP (1) | JP6906520B2 (OSRAM) |
| KR (1) | KR20180086233A (OSRAM) |
| CN (1) | CN108289903B (OSRAM) |
| AU (1) | AU2016362993A1 (OSRAM) |
| BR (1) | BR112018011261A2 (OSRAM) |
| CA (1) | CA3005997A1 (OSRAM) |
| EA (1) | EA201891340A1 (OSRAM) |
| IL (1) | IL259479B (OSRAM) |
| MX (1) | MX385283B (OSRAM) |
| SG (2) | SG10202005298RA (OSRAM) |
| WO (1) | WO2017096274A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2625768C2 (ru) | 2010-08-05 | 2017-07-18 | Сиэтл Дженетикс, Инк. | Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EA201992875A1 (ru) * | 2017-06-07 | 2020-03-25 | Сиэтл Дженетикс, Инк. | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения |
| US11911404B2 (en) * | 2017-10-13 | 2024-02-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune surveillance in melanoma |
| EP3841123A2 (en) | 2018-08-23 | 2021-06-30 | Seagen Inc. | Anti-tigit antibodies |
| US20220081477A1 (en) * | 2018-12-19 | 2022-03-17 | Seagen Inc. | Controlled fucosylation of antibodies |
| US20220305038A1 (en) * | 2019-08-16 | 2022-09-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN111973749B (zh) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | 一种抗肿瘤免疫治疗的药物组合物 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2022221766A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN113274502B (zh) * | 2021-05-05 | 2023-01-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于特定型三阴乳腺癌免疫治疗的组合物 |
| US20240238318A1 (en) * | 2021-05-06 | 2024-07-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | L-fucose and anti-androgen receptor therapy for treatment of cancer |
| CN113413465B (zh) * | 2021-06-15 | 2022-06-03 | 北京大学 | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 |
| CN115466297B (zh) * | 2022-08-25 | 2023-07-07 | 青岛农业大学 | L-岩藻糖的应用以及动物饲料 |
| WO2024077106A2 (en) * | 2022-10-04 | 2024-04-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2625768C2 (ru) * | 2010-08-05 | 2017-07-18 | Сиэтл Дженетикс, Инк. | Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы |
| JP2016540042A (ja) * | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ， インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
-
2016
- 2016-12-02 WO PCT/US2016/064783 patent/WO2017096274A1/en not_active Ceased
- 2016-12-02 AU AU2016362993A patent/AU2016362993A1/en not_active Abandoned
- 2016-12-02 SG SG10202005298RA patent/SG10202005298RA/en unknown
- 2016-12-02 US US15/781,256 patent/US20180353524A1/en not_active Abandoned
- 2016-12-02 MX MX2018006674A patent/MX385283B/es unknown
- 2016-12-02 CA CA3005997A patent/CA3005997A1/en not_active Abandoned
- 2016-12-02 BR BR112018011261A patent/BR112018011261A2/pt not_active Application Discontinuation
- 2016-12-02 SG SG11201804263PA patent/SG11201804263PA/en unknown
- 2016-12-02 JP JP2018528650A patent/JP6906520B2/ja active Active
- 2016-12-02 CN CN201680071076.0A patent/CN108289903B/zh not_active Expired - Fee Related
- 2016-12-02 EP EP16871645.4A patent/EP3383404A4/en not_active Withdrawn
- 2016-12-02 KR KR1020187017824A patent/KR20180086233A/ko not_active Withdrawn
- 2016-12-02 EA EA201891340A patent/EA201891340A1/ru unknown
-
2018
- 2018-05-21 IL IL259479A patent/IL259479B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180353524A1 (en) | 2018-12-13 |
| KR20180086233A (ko) | 2018-07-30 |
| CA3005997A1 (en) | 2017-06-08 |
| EP3383404A1 (en) | 2018-10-10 |
| IL259479A (en) | 2018-07-31 |
| EP3383404A4 (en) | 2019-07-31 |
| AU2016362993A1 (en) | 2018-07-12 |
| JP2019501145A (ja) | 2019-01-17 |
| SG11201804263PA (en) | 2018-06-28 |
| MX2018006674A (es) | 2018-11-09 |
| EA201891340A1 (ru) | 2018-11-30 |
| MX385283B (es) | 2025-03-18 |
| JP6906520B2 (ja) | 2021-07-21 |
| WO2017096274A1 (en) | 2017-06-08 |
| SG10202005298RA (en) | 2020-07-29 |
| CN108289903A (zh) | 2018-07-17 |
| CN108289903B (zh) | 2021-08-03 |
| BR112018011261A2 (pt) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| FIC20250023I1 (fi) | Latsertinibi kaikissa peruspatentin suojaamissa muodoissa | |
| IL259162B (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| SI3283527T1 (sl) | Kombinirana terapija proti raku | |
| HUE070659T2 (hu) | KDM1A inhibitor és annak felhasználása terápiában | |
| PL2976106T3 (pl) | Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor | |
| DK3298845T3 (da) | Programmering i licensunderstøttet tilgang | |
| HUE058323T2 (hu) | Egy BTK-inhibitor rák kezelésében történõ alkalmazásra | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3230318T3 (da) | Immune checkpoint-inhibitor-kombinationer | |
| DK4119569T3 (da) | Konjugerede antisense-forbindelser til anvendelse i behandling | |
| MA41176A (fr) | Complexes radio-pharmaceutiques | |
| HUE040167T2 (hu) | Rákkezelés | |
| PT3463436T (pt) | Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| FI20145740A7 (fi) | Sovitelma puomistossa | |
| DK3380468T3 (da) | Bis-pyridazinforbindelser og anvendelse heraf i behandling af cancer | |
| DK2979704T3 (da) | Desmoglein-3-peptider i pemphigus vulgaris | |
| DK3164195T3 (da) | Glutaminaseinhibitorterapi | |
| HK1262072A1 (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| FI10846U1 (fi) | Sovitelma saunan yhteydessä | |
| TH1501006324A (th) | การบำบัดมะเร็งด้วยไดไฮโดรพิแรซิโน-พิแรซีน | |
| BR302014001882S1 (pt) | Configuração aplicada em solado | |
| BR302014001777S1 (pt) | Configuração aplicada em solado |